Jochen Utikal
Utikal, Jochen 1974-
VIAF ID: 268302420 ( Personal )
Permalink: http://viaf.org/viaf/268302420
Preferred Forms
-
100 0 _
‡a
Jochen Utikal
-
100 1 _
‡a
Utikal, Jochen
‡d
1974-
-
100 1 _
‡a
Utikal, Jochen
‡d
1974-
4xx's: Alternate Name Forms (5)
Works
| Title | Sources |
|---|---|
| Eosinophils as biomarker in melanoma immunotherapy and solid tumors |
|
| Immortalization eliminates a roadblock during cellular reprogramming into iPS cells |
|
| The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. |
|
| Impact of preconditioning with retinoic acid during early development on morphological and functional characteristics of human induced pluripotent stem cell-derived neurons. |
|
| Improved survival with MEK inhibition in BRAF-mutated melanoma |
|
| Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma |
|
| Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. |
|
| Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular Dystrophy |
|
| Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report. |
|
| Liquid biopsy to monitor melanoma patients. |
|
| Local cutaneous argyria mimicking melanoma metastases in a patient with disseminated melanoma |
|
| Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation |
|
| Loss of tumorigenic potential upon transdifferentiation from keratinocytic into melanocytic lineage. |
|
| MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma. |
|
| Mechanisms of p53 restriction in Merkel cell carcinoma cells are independent of the Merkel cell polyoma virus T antigens. |
|
| Mediators of induced pluripotency and their role in cancer cells - current scientific knowledge and future perspectives. |
|
| Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response. |
|
| Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. |
|
| Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma |
|
| Molecular genetics of Xeroderma pigmentosum variant. |
|
| Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals |
|
| mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. |
|
| A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. |
|
| Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy. |
|
| Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. |
|
| Multiple roles of NF1 in the melanocyte lineage. |
|
| Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib |
|
| MYC gene amplification is a rare event in atypical fibroxanthoma and pleomorphic dermal sarcoma. |
|
| Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up |
|
| Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. |
|
| NF1 loss induces senescence during human melanocyte differentiation in an iPSC-based model. |
|
| Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. |
|
| Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway |
|
| Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer. |
|
| The oak processionary moth: a new health hazard? |
|
| Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. |
|
| Opposing roles of eosinophils in cancer |
|
| Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. |
|
| The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. |
|
| Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma. |
|
| [Persistent facial erythema and edema]. |
|
| Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. |
|
| PIEZO2 is required for mechanotransduction in human stem cell-derived touch receptors. |
|
| Predictive immune markers in advanced melanoma patients treated with ipilimumab. |
|
| Predominant telangiectatic erythema in linear atrophoderma of Moulin: novel variant or separate entity? |
|
| Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma. |
|
| Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study. |
|
| The receptor for interleukin-17E is induced by Th2 cytokines in antigen-presenting cells |
|
| Recurrent tattoo reactions in a patient treated with BRAF and MEK inhibitors |
|
| [Red and purple maculas and plaques at the lateral aspects of the thighs]. |
|
| Reiter's syndrome-like pattern in AIDS-associated psoriasiform dermatitis |
|
| Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. |
|
| RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas |
|
| The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression |
|
| Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. |
|
| Sentinel node metastasis mitotic rate (SN-MMR) as a prognostic indicator of rapidly progressing disease in patients with sentinel node-positive melanomas. |
|
| Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma |
|
| Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer. |
|
| Serum of patients with acute myocardial infarction prevents inflammation in iPSC-cardiomyocytes |
|
| The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation. |
|
| Single cell polarity in liquid phase facilitates tumour metastasis. |
|
| [Single center analysis of the dermatosurgical patient cohort of a tumor center in Germany] |
|
| SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma |
|
| SOX5 is involved in balanced MITF regulation in human melanoma cells. |
|
| Subtype-specific differentiation of cardiac pacemaker cell clusters from human induced pluripotent stem cells. |
|
| Systemic therapy of non-resectable metastatic melanoma. |
|
| T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin |
|
| Tackling malignant melanoma epigenetically: histone lysine methylation |
|
| Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe) |
|
| Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts |
|
| Targeting SOX2 in anticancer therapy |
|
| The telomere profile distinguishes two classes of genetically distinct cutaneous squamous cell carcinomas. |
|
| TGF-β induces SOX2 expression in a time-dependent manner in human melanoma cells |
|
| Timed Ang2-targeted therapy identifies the Angiopoietin-Tie pathway as key regulator of fatal lymphogenous metastasis |
|
| Topography of cancer-associated immune cells in human solid tumors |
|
| Treatment of gunpowder tattoos with a high-speed diamond drill |
|
| Ultraviolet exposure and risk of melanoma and basal cell carcinoma in Ulm and Dresden, Germany. |
|
| Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma |
|
| Update on GNA Alterations in Cancer: Implications for Uveal Melanoma Treatment |
|
| Willingness to pay for a cure of low-risk melanoma patients in Germany. |
|
| Zweites Netzwerktreffen der zertifizierten Hauttumorzentren |
|
